MC2 and Almirall clear crucial obstacle to psoriasis treatment in Europe

Psoriasis cream Wynzora has safely traversed the decentralized procedure route to approval in Europe, which paves the way for individual national health authorities to vouch for the treatment.
Photo: MC2 Therapeutics / PR
Photo: MC2 Therapeutics / PR

Danish company MC Therapeutics' psoriasis cream Wynzora has cleared another obstacle on the way to the EU markets.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading